Hoffmann-la Roche Inc.

C4 Therapeutics, Inc.

Alkermes, Inc.

Rodin Therapeutics, Inc.

C4 Therepeutics, Inc.

F. Hoffmann-la Roche Ag

Fabian Dey

Wei Zhu

Roger David Norcross

Hong Shen

Annick Goergler

Ge Zou

Eric Andre Kusznir

Hongtao Xu

Zhiwei Zhang

Weixing Zhang

Martin R Jefson

Philipp Schmid

Andreas Schoop

John Adams Lowe, Iii

Christopher G Nasveschuk

Hongying Yun

Andreas Bergmann

Bernd Kuhn

Lisha Wang

Nathan Oliver Fuller

Zongxing Qiu

Adrian Britschgi

Moreno Attilio Wichert

Stephan Roever

Konrad H Bleicher

Xuefei Tan

Taishan Hu

Yongfu Liu

Mingwei Zhou

Ge Zhu

Russell Thomas

Dongdong Chen

Guolong Wu

Xiao Ding

Haixia Liu

Zhisen Zhang

Xianfeng Lin

Buyu Kou

Carsten Kroll

Shixiang Yan

Chengang Zhou

Yimin Hu

Houguang Shi

Jianguo Chen

Xiaoqing Wang

Jérôme Hert

Yongqiang Liu

Yafei Liu

Adrian Schomburg

Lue Dai

Maarten Vercruysse

Konstanze Konig Von Paumbshausen

Dong Ding

Konrad Bleicher

Linuo Zhu

John A Iii Lowe

The present invention relates to compounds of formula (I), wherein Rto Rand n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Triazatricycle compounds for the treatment of autoimmune disease

Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds act as antagonists of the toll-like receptors TLR7, TLR8 and/or TLR9 and are thus useful in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease

The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Dihydrobenzimidazolones for medical treatment

The present invention relates to compounds of formula (I), wherein R, R, Rand Rare as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Pyrazolopyridine compounds for the treatment of autoimmune disease

The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Spirocyclic compounds

The present invention relates to compounds of formula (I), wherein Rto R, m and n are I a described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease

The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Dihydroquinolinones for medical treatment

The present invention relates to compounds of formula (I), wherein Rto Rare as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Piperazine compounds for the treatment of autoimmune disease

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Hetero-halo inhibitors of histone deacetylase

The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Glutarimides for medical treatment

The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease

The present invention relates to compounds of formula (I), (I), wherein R, Rand Rare as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds. 

Benzothiazole compounds for the treatment of autoimmune diseases

The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Growing community of inventors

Basel, Switzerland

Fabian Dey